Stocks
Intraday Booster
Sector Booster
Stock Screener
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersStock Screener
Create Screener
Explore Screeners
Community Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNew
EMA Screener
SMA Screener
WMA Screener
OHLC Screener
Fibonacci Screener
VWAP Screener
Pivot Point Screener
Overlay Screener
Trend Indicator Screener
Volume Based Indicator Screener
Overbought/Sold Screener
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMore
Global Market Today
Global Indices
Indian Indices
NIfty Today
Gold Price TodayNew
Silver Price TodayNew
Platinum Price TodayNew
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataSector Booster
FnO Movements
NSE F&O Lot Size
Ban List
Technical Dashboard
Sector AnalysisNew
Result Calendar
IPO Calendar
Economic Calendar
Epigral
Epigral Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Epigral Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Epigral Ltd trades at a P/E of 15.22× and P/B of 2.41×.
Valuation
Profitability
Growth
Financial Health
Epigral Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Epigral Ltd, switchable between annual and quarterly views, consolidated or standalone.
Epigral Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹4,797.32 Cr and reported EPS of ₹76.97.
Epigral segment analysis: revenue and profit mix.
Disclosed business segments at Epigral with their share of revenue and profit, switchable between consolidated and standalone reporting.
Epigral discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Epigral Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Epigral Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Epigral Ltd's investment case rests on 7 positive markers and 7 flagged concerns drawn from the latest reported filings.
What you're getting.
Epigral Ltd boasts a robust ROE of 22.60% and a high OPM of 27.80%, showcasing efficient operations and strong returns on investment. Its healthy ROCE of 25.10% further reinforces this financial strength.
The company demonstrates impressive quarterly profit growth, surging by 87.10%. This significant increase points to robust product demand and effective management strategies driving profitability.
Epigral's current PE ratio of 17.10 is notably lower than the sector PE of 22.35, suggesting potential undervaluation. This favorable valuation could present an attractive entry point for investors seeking growth.
A substantial promoter holding of 68.83% indicates strong confidence from the company's founders and management. This high stake often aligns management's interests with long-term shareholder value creation.
Operating in the 'Specialty Chemicals' sector, Epigral is well-positioned to capitalize on the growing demand for specialized chemical products. This industry expansion offers significant long-term growth potential.
What can break it.
Epigral Ltd's debt-to-equity ratio stands at 0.31, suggesting a moderate level of financial leverage. This could heighten financial risk, particularly during economic downturns or unexpected market shifts.
While quarterly profits show strong growth, quarterly sales have experienced a concerning -6.86% variance, signaling a potential slowdown in sales growth that warrants further investigation.
Although promoter holding is substantial at 68.83%, a recent decrease from 71.58% raises investor concerns. This decline in promoter stake warrants close monitoring to assess potential ownership shifts.
The current stock price of 1712.00 is significantly closer to its 52-week low of 1502.35 than its high of 2242.55. This indicates recent underperformance and potential investor caution in the short term.
Epigral operates in a competitive 'Specialty Chemicals' market with established players like Pidilite Inds. and Deepak Nitrite. Intense competition could pressure margins and market share, impacting profitability.
What would change my mind.
Trim if P/E re-rates above 20. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 26.25. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 11%. The operating engine is no longer compounding capital efficiently.
Epigral Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Epigral Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
 Aarti Industries Ltd |
 Aarti Surfactants Ltd |
 Archean Chemical Industries Ltd |
 Aether Industries Ltd |
 Alkali Metals Ltd |
 Alkyl Amines Chemicals Ltd |
 Anupam Rasayan India Ltd |
 Atul Ltd |
 Balaji Amines Ltd |
 BASF India Ltd |
 Bhansali Engineering Polymers Ltd |
 Camlin Fine Sciences Ltd |
 Chembond Material Technologies Ltd |
 Chemcon Speciality Chemicals Ltd |
 Clean Science & Technology Ltd |
 Deepak Nitrite Ltd |
 Diamines & Chemicals Ltd |
 DMCC Speciality Chemicals Ltd |
 Dynemic Products Ltd |
Epigral LtdCurrent Stock |
 Excel Industries Ltd |
 Fairchem Organics Ltd |
 Fineotex Chemical Ltd |
 Fine Organic Industries Ltd |
 Gujarat Fluorochemicals Ltd |
 Foseco India Ltd |
 Galaxy Surfactants Ltd |
 HP Adhesives Ltd |
 Indo Amines Ltd |
 IVP Ltd |
 Jayant Agro Organics Ltd |
 Jubilant Agri & Consumer Products Ltd |
 Jubilant Ingrevia Ltd |
 Kronox Lab Sciences Ltd |
 Laxmi Organic Industries Ltd |
 Navin Fluorine International Ltd |
 Neogen Chemicals Ltd |
 NOCIL Ltd |
 Oriental Aromatics Ltd |
 Pidilite Industries Ltd |
 Plastiblends India Ltd |
 Platinum Industries Ltd |
 Privi Speciality Chemicals Ltd |
 Rossari Biotech Ltd |
 S H Kelkar & Company Ltd |
 Styrenix Performance Materials Ltd |
 Tatva Chintan Pharma Chem Ltd |
 Valiant Organics Ltd |
 Vidhi Specialty Food Ingredients Ltd |
 Vikas Ecotech Ltd |
 Vinati Organics Ltd |
 Vishnu Chemicals Ltd |
 Yasho Industries Ltd |
Epigral Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Epigral Ltd — derived from the live tape, not yesterday's close.
Epigral Ltd last traded at ₹1,113.8 with an intraday range of ₹1,110–₹1,140 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1113.80| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1192.53 | +78.73 | +7.07% |
| R3 | 1162.53 | +48.73 | +4.38% |
| R2 | 1151.27 | +37.47 | +3.36% |
| R1 | 1132.53 | +18.73 | +1.68% |
| PIVOT | 1121.27 | 7.47 | 0.67% |
| CURRENT | 1113.80 | — | — |
| S1 | 1042.53 | -71.27 | -6.40% |
| S2 | 1072.53 | -41.27 | -3.71% |
| S3 | 1091.27 | -22.53 | -2.02% |
| S4 | 1102.53 | -11.27 | -1.01% |
EPIGRAL is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 1125 ~ 1140
Trading Below opening range, showing Bearishness
Epigral Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Epigral Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Epigral Ltd stood at 57.2% of traded volume, against a 20-day average of 51.6%.
Epigral announcements: results, concalls, ratings, M&A.
Filings Epigral sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Epigral dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Epigral has declared, sequenced by announce and record date.
Epigral corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Epigral Ltd: business, sector, key facts.
What Epigral Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Epigral Ltd operates in the Basic Materials, listed as NSE: EPIGRAL, BSE: 543332.
Epigral Limited is a prominent Indian manufacturer and seller of chlor-alkali and related chemical derivatives, operating both domestically and internationally. Their extensive product portfolio caters to a diverse range of industries, showcasing their broad reach and diverse applications within the chemical sector. The company's history, starting as Meghmani Finechem Limited before a name change in August 2023, highlights its growth and evolution in the market.
A core component of Epigral's business is the production and sale of chlorinated polyvinyl chloride (CPVC) resins and compounds. These materials find significant application in the manufacturing of CPVC pipes and fittings, demonstrating a key vertical integration within their operations. Beyond CPVC, Epigral also produces and supplies a wide array of other chemical products, including epichlorohydrin, various chloromethanes, hydrogen peroxide, caustic soda, potash, chlorine, and hydrogen. These products are further processed into other value-added chemicals like chlorotoluene, highlighting a commitment to comprehensive chemical manufacturing.
The breadth of industries served by Epigral underscores the versatility and demand for their chemical products. Their customer base spans sectors such as construction (using CPVC pipes), paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergent manufacturing, and various others, including the production of fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and even PTFE pipes. This wide reach indicates Epigral’s strategic positioning across many crucial industrial sectors.
Epigral’s operations are not limited to chemical production; they also feature a significant energy component. The company operates a captive power plant (CPP) to support its manufacturing processes, ensuring a reliable and cost-effective energy supply. Furthermore, they have invested in renewable energy sources by operating a wind-solar hybrid power plant, demonstrating a commitment to sustainable practices and energy independence. This integrated approach to energy production underlines their commitment to operational efficiency and environmental responsibility.
Questions investors ask about Epigral Ltd (EPIGRAL).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Epigral Ltd (EPIGRAL)?
The current share price of Epigral Ltd (EPIGRAL) is ₹1,113.8. Today, the stock has declined by ₹35.90 (3.12%), trading in a range of ₹1,110 to ₹1,140. The stock opened at ₹1,135 with a trading volume of 33,337 shares.
02Is Epigral Ltd stock a good investment for long-term?
Epigral Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹4,797.32 crores, P/E ratio of 15.22, ROE of 16.09%, and ROCE of 25.10%. The dividend yield stands at 0.44%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Epigral Ltd stock?
The 52-week high price of Epigral Ltd (EPIGRAL) is ₹2,114, while the 52-week low is ₹807. Currently trading at ₹1,113.8, the stock is 23.5% away from its 52-week low and 47.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Epigral Ltd stock at the current price?
Whether to buy Epigral Ltd stock at ₹1,113.8 depends on multiple factors. The stock is currently trading with a P/E ratio of 15.22 and P/B ratio of N/A. Today's performance shows a loss of 3.12%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Epigral Ltd and when is the next dividend?
Epigral Ltd offers a dividend yield of 0.44%, which means for every ₹100 invested at the current price of ₹1,113.8, you can expect to receive approximately ₹0.44 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Epigral Ltd?
Epigral Ltd's key financial metrics include: P/E Ratio: 15.22, P/B Ratio: N/A, ROE: 16.09%, ROCE: 25.10%, Dividend Yield: 0.44%, EPS: ₹76.97, Book Value: ₹486.92, Debt-to-Equity: 25.75, and Current Ratio: N/A. The company's market cap stands at ₹4,797.32 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Epigral Ltd stock performing today in the market?
Epigral Ltd stock opened at ₹1,135 and is currently trading at ₹1,113.8, showing a decline of ₹35.90 (3.12%). The intraday high is ₹1,140 and low is ₹1,110. The trading volume stands at 33,337 shares, indicating moderate market participation today.
08What is the P/E ratio of Epigral Ltd and what does it indicate?
Epigral Ltd has a Price-to-Earnings (P/E) ratio of 15.22, which means investors are willing to pay ₹15.22 for every ₹1 of earnings. With an EPS of ₹76.97, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Epigral Ltd (EPIGRAL) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarti Industries (AARTIIND) Share PricePeer
- Aarti Surfactants (AARTISURF) Share PricePeer
- Archean Chemical Industries (ACI) Share PricePeer
- Aether Industries (AETHER) Share PricePeer
- Alkali Metals (ALKALI) Share PricePeer
- Top Losers TodayScreener
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Menu